Immuron (IMRN) Return on Capital Employed (2019 - 2024)
Immuron (IMRN) posted quarterly Return on Capital Employed of 56732272386225.71% for Q4 2024, up 5673227238627568.0% year-over-year from N/an in Q1 2024, and up 113540512685998.4% quarter-over-quarter from 49.97% in Q4 2023.
Immuron (IMRN) Return on Capital Employed (2019 - 2024) Analysis & Trends
Immuron's Return on Capital Employed history runs 5 years deep, the most recent figure standing at 56732272386225.71% for Q4 2024.
- In Q4 2024, Return on Capital Employed rose 5673227238627568.0% year-over-year to 56732272386225.71%; the TTM figure through Dec 2024 stood at 56732272386225.71% (up 5673227238627568.0% YoY), while the FY2025 annual figure was 166.05%, down 13738.0% from the prior year.
- Return on Capital Employed for Q4 2024 stood at 56732272386225.71%, up from 49.97% in the prior quarter.
- The five-year high for Return on Capital Employed was 56732272386225.71% in Q4 2024, with the low at 49.97% in Q4 2023.
- The 4-year median for Return on Capital Employed is 17.22% (2021), against an average of 11346454477226.26%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed sank 4719 bps in 2023, then soared 2000000000 bps in 2024.
- Immuron's Return on Capital Employed stood at 17.22% in 2021, then surged by 84 bps to 2.77% in 2022, then slumped by 1702 bps to 49.97% in 2023, then soared by 2000000000 bps to 56732272386225.71% in 2024.
- Business Quant data shows IMRN's Return on Capital Employed at 56732272386225.71% in Q4 2024, 49.97% in Q4 2023, and 24.49% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Immuron | 6.81 Mn | 6.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 56,732,272,386,225.71% |
| Dec 31, 2023 | -49.97% |
| Jun 30, 2023 | -24.49% |
| Dec 31, 2022 | -2.77% |
| Dec 31, 2021 | -17.22% |
| Dec 31, 2019 | 158.47% |